Follicular Lymphoma. 1. Introduction. 2. Diagnosis. 3. Baseline Investigations
|
|
- Jasmin Carter
- 8 years ago
- Views:
Transcription
1 Follicular Lymphoma Follicular Lymphoma Treatment policy prepared by Dr. Louise Bordeleau 1. Introduction Follicular lymphoma is the second most frequent type of non-hodgkin s lymphoma. These lymphomas are classified as follicular small cleaved cell, follicular mixed cell and follicular large cell lymphoma in the Working Formulation [1]. According to the WHO classification, this entity is classified as follicle center cell lymphoma, follicular grade 1 (small cleaved cell), grade 2 (mixed small and large cell) and grade 3 (large cell) [2]. 2. Diagnosis The diagnosis of follicular lymphoma is dependent on an adequate biopsy specimen (preferable open surgical biopsy) with immunohistochemistry. This lymphoma is composed of follicle center cells, usually a mixture of centrocytes (cleaved follicle center cells) and centroblasts (large non-cleaved follicle center cells). The pattern is at least partially follicular, but diffuse areas may be present. The tumor cells are usually surface immune globulin +, B-cell-associated antigen + (CD 19, 20, 79a). Lack of CD5 and CD43 is useful in distinguishing follicle center lymphoma from mantle cell lymphoma and the presence of CD10 can be useful in distinguishing it from marginal zone cell lymphomas [2]. 3. Baseline Investigations The following investigations are indicated for most patients with follicular lymphoma: Pathology review CBC, differential, blood film Serum electrolytes and creatinine Liver function tests Serum LDH Serum protein electrophoresis Serum uric acid Chest x-ray CT chest, abdomen and pelvis Unilateral bone marrow biopsy Toronto-Sunnybrook Regional Cancer Centre Hematology Site Group - Treatment Policies 1/10
2 Patients who will be managed with palliative intent may have more limited staging investigations with a focus on identification of disease that is likely to require symptomatic management. Bone marrow biopsy may not be necessary in patients who are not eligible for experimental treatments or curative radiotherapy. HIV Serology As follicular lymphoma is not usually associated with HIV infection, testing should be limited to patients at risk of such an infection especially if choice of treatment would be affected. Cardiac Assessment A cardiac assessment should be performed in all patients planned to receive an anthracycline-based chemotherapy (such as CHOP). MUGA scan or 2Dechocardiogram should be performed for those patients if known to have a history of: Age > 60 years Hypertension Congestive heart failure Peripheral vascular disease Cerebrovascular disease Angina Cardiac arrhythmia Myocardial infarction Gallium Scan Gallium scans are not routinely recommended, but may be required for patients on experimental therapy. 4. Staging Patients with follicular lymphoma should be staged according to both the Ann Arbor and the IPI staging systems. Ann Arbor Stage The Ann Arbor staging system continues to be in use in follicular lymphoma. This system provides limited prognostic information, but is of use in determining therapeutic management. All patients should have an Ann Arbor stage assigned. 2/10
3 Follicular Lymphoma Stage Definition I II III IV Involvement of a single lymph node region or a single extranodal site. Involvement of two or more lymph nodes on the same side of the diaphragm or localized involvement of an extra lymphatic organ or site and one or more lymph nodes on the same side of the diaphragm. Involvement of lymph node regions on both sides of the diaphragm that may also be accompanied by involvement of the spleen or by localized involvement of an extra lymphatic organ or site or both. Diffuse or disseminated involvement of one or more extra lymphatic organs or tissues, with or without associated lymph node involvement. The absence or presence of fever > 38.5 C, drenching night sweats, and/or unexplained weight loss of 10 percent or more body weight in the six months preceding admission are to be denoted in all cases by the suffix A or B respectively. The International Prognostic Factor Index The International Prognostic Index (IPI) for aggressive non-hodgkin s lymphomas has been found to be an important prognostic tool in low-grade lymphomas [3, 4]. The IPI index is dependent on five prognostic factors: age, Ann Arbor stage, performance status, LDH and number of extranodal sites. Based on the IPI, tenyear overall survival rates for the risk groups are as follows: low, 73.6%; lowintermediate, 45.2%; high-intermediate, 53.5%; and high, 0% (P, 0.001) [3]. In patients with stage III-IV, B symptom(s), age greater than 60 years, and at least three nodal sites greater than 3cm were significant prognostic variables on multivariate analysis. The IPI used in patients with stage III-IV was also significant for progression-free and overall survival [4]. The main limitation of the IPI in patients with follicular lymphoma is that prognostic subgroups do not have a good discriminating power [5]. A number of other prognostic factors have also been studied. Presence of helper T- cell infiltrates and normal hemoglobin have been associated with a favorable prognosis, whereas absence of inter-follicular fibrosis, increased nuclear proliferation, cytogenetics abnormalities, male gender, bulky tumor, hepatosplenomegaly, > 20% bone marrow involvement and a B2 microglobulin > 3 have been associated with unfavorable prognosis. The prognosis value of the number of large cells and the architecture remains equivocal [6]. Toronto-Sunnybrook Regional Cancer Centre Hematology Site Group - Treatment Policies 3/10
4 (A) Survival curves of 125 patients according to the International Index (low v low-intermediate v high-intermediate v high risk: P <.001; low-intermediate risk: not significant). (B) Survival curves after merging groups with low-intermediate and high-intermediate risk (P <.001) [3]. 5. Management of Follicular Grade I-II Patients with localized disease at presentation (stage I-II) may be cured by radiotherapy. Relapse free survival (RFS) is found to be ranging from 55-60% at 5 years and 40-55% at 10 years [7]. Over 25% of patients treated with radiotherapy are unlikely to relapse at any time in the future with RFS of 55% +/- 15% at 15 years for patients with stage I disease and 29% +/- 14% for patients with stage II disease [8]. Long-term disease control within radiation fields can be achieved in a significant number of patients by using doses of radiation that usually range from 2,500 to 4,000 cgy to involved sites or to extended fields, which cover adjacent nodal sites [9,10,11,8]. The value of adjuvant chemotherapy, in addition to radiation to decrease relapse, has not been proven conclusively [12,13]. Most patients will be treated to a dose of 3600 cgy in 18 fractions. For patients with involvement not encompassable by radiation therapy or patients for whom radiation therapy is contraindicated, we recommend treatment as described for the advanced stage. 4/10
5 Follicular Lymphoma Advanced Stage Disease The majority of patients with follicular lymphoma have disseminated disease at presentation and remain incurable with present therapeutic approaches. Current management strategies includes a watch and wait policy, the use of oral alkylating agents (such as chlorambucil or cyclophosphamide), newer purine analogues (fludarabine, 2-CDA) and combination chemotherapy with or without interferon. The optimal treatment is controversial, as the vast majority of patients with advanced stages of follicular lymphoma are not cured with the current therapeutic options. In addition, prolongation of survival has been difficult to demonstrate. Innovative approaches are under clinical evaluation. Watch and Wait Policy: Early intervention has shown no survival advantage to the watch and wait policy [14,15]. This watch and wait policy requires symptomatic disease, before institution of therapy. Once symptomatic, local or systemic therapy is indicated. Systemic Therapy: Systemic therapy should be initiated in symptomatic patients. A variety of treatment options are available: (a) Oral Alkylating Agents (with or without steroids): Chlorambucil and subsequently cyclophosphamide have almost invariably been included in first line treatment of follicular lymphoma since the efficacy of the drugs was first reported [16,17]. (b) Purines Analogues: The treatment efficacy of single-agent purine analogues (fludarabine, 2-chlorodeoxyadenosine) approaches that of the alkylating agents [18,19,20]. (c) Combination Chemotherapy: Combination chemotherapy, such as CVP (cyclophosphamide, vincristine and prednisone) have also been compared to single alkylating agent in the treatment of follicular lymphomas. Although CVP was found to prolong the duration of first remission, the overall response rate and overall survival were equivalent to single agent therapy [21,22]. The addition of adriamycin to CVP (i.e. CHOP) has resulted in a higher remission rate with no significant influence on survival [23]. We recommend watch and wait in asymptomatic patients (+/- bulk). In symptomatic patients with life-threatening disease or rapid progression, we recommend CVP. Other patients should be offered chlorambucil +/- prednisone as initial therapy. CHOP is almost never used as initial therapy. The Role of Interferon Alpha CCO EBR 6-10 Data for the use of interferon maintenance therapy suggest prolonged disease-free survival, but no consistent overall survival benefit [24,25,26]. The role for interferon in patients with follicular lymphoma remains under clinical evaluation. Toronto-Sunnybrook Regional Cancer Centre Hematology Site Group - Treatment Policies 5/10
6 The Role of Dose Intense Therapy with Stem Cell Support The use of autologous bone marrow transplantation in first remission remains investigational. Assessment of Response Responses are classified according to the Cheson criteria (Appendix C). Treatment objectives are to achieve symptomatic control of the disease as well as to prevent potential complications. The achievement of complete remission is not a treatment goal. Management of Incomplete Responders Unless symptomatic, patients with incomplete response should be observed carefully. Treatment (systemic or local) should be offered at the time of disease progression. Follow Up For advanced disease, recurrence is inevitable. The median time to progression is 31 months, with an overall median survival of 6 to 10 years [27,23]. Patients should be followed every 3-4 months for the first 2 years and every 6-12 months thereafter. Assessment should consist of: History & physical exam CBC and differential Liver function tests Creatinine Serum LDH Imaging of involved areas with US +/- CXR should be performed after completion of treatment as a baseline for future comparison. Routine surveillance imaging is an inefficient means of identifying relapse and should be restricted to patients felt to be at high risk of vital organ compromise. Patients wishes should be considered when planning follow up investigations. 6. Follicular Grade III (Follicular Large Cell) Follicular large cell lymphoma (FLCL) is a rare disease that represents ~ 3% of all NHL [2]. FLCL is supposed to have an intermediate prognosis between other follicular lymphomas and the more aggressive diffuse large-cell lymphoma [28]. FLCLs may have sustained remission after standard anthracycline-based chemotherapy (such as CHOP) and therefore are often treated as aggressive lymphomas [28]. This remains an area of controversy. Patients with follicular large cell NHL should be treated similarly to those with diffuse large B-cell lymphoma (see Diffuse Large B-Cell Lymphoma). 6/10
7 Follicular Lymphoma 7. Management of Relapsed Disease Relapse with follicular low-grade non-hodgkin s lymphoma is inevitable in patients with advanced disease and common in patients with localized disease. Although patients often respond again to the same or a similar induction regimen, the quality of their response becomes worse and the duration shorter. Favorable survival after relapse has been associated with age younger than 60 years, complete remission rather than partial remission, and duration of response longer than 1 year [29]. Relapse with both indolent or aggressive histology (histologic conversion) may occur. Biopsy should be performed if the clinical pattern of relapse suggests that the disease is behaving in a more aggressive manner, has rapid growth or discordant growth between various disease sites. Relapse with Indolent Lymphoma CCO EBR 6-8 Patients who experience a relapse with indolent lymphoma can often have their disease controlled with palliative radiation or systemic therapy. Consideration to experimental therapies should be given at this time. Otherwise, we recommend chlorambucil +/- prednisone if remission duration > 1 year. If remission duration is < 1 year, combination chemotherapy such as CVP can be used first. Significant activity for purine analogues has also been demonstrated in relapsed low-grade lymphomas, either as a single agent [30,31,18] or in combination with other drugs [32]. An anti-cd20 monoclonal antibody results in a 40-50% response rate in patients who relapse with indolent B-cell lymphomas [33]. Radio-labeled monoclonal antibodies are presently under investigation. Bone marrow transplantation is still under evaluation, but can be considered [34]. The therapy of relapsed follicular low-grade lymphoma should be individualized. A sequence appropriate for most patients would consist of the following: Chlorambucil CVP Fludarabine Rituximab Relapse with Histologic Conversion Patients with histologic conversions should be treated with the regimens described in the aggressive, recurrent adult NHL section (CHOP X 6 cycles). A subset of patients with histologic transformation enjoys relatively long-term survival. Patients with limited disease and no previous exposure to chemotherapy have the most favorable prognosis [35]. The addition of radiotherapy can also be considered in patients with residual localized low-grade NHL. Toronto-Sunnybrook Regional Cancer Centre Hematology Site Group - Treatment Policies 7/10
8 8. References 1. Armitage JO, Weisenburger DD. New approach to classifying non-hodgkin s lymphomas: clinical features of the major histologic subtypes. J Clin Oncol Aug;16(8): Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study group. Blood Sep 1;84(5): Lopez-Guillermo A, Montserrat E, Bosch F, et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol Jul;12(7): Decaudin D, Lepage E, Brousse N, et al. Low-grade stage III-IV follicular lymphoma; multivariate analysis of prognostic factors in 484 patients--a study of the groupe d Etude des lymphomes de l Adulte. J Clin Oncol Aug;17(8): Bastion Y, Coiffier B. Is the International Prognostic Index for Aggressive Lymphoma patients useful for follicular lymphoma patients? J Clin Oncol Jul;12(7): Horning SJ. Natural history of and therapy for the indolent non-hodgkin s lymphomas. Semin Oncol Oct;20(5 Suppl 5): Pendlebury S, el Awadi M, Ashley S, et al. Radiotherapy results in early stage low grade nodal non-hodgkin s lymphoma. Radiother Oncol Sep;36(3): Denham JW, Denham E, Dear KB, Hudson GV. The follicular non-hodgkin s lymphomas--i. The possibility of cure. Eur J Cancer Mar;32A(3): Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol Apr;14(4): Lawrence TS, Urba WJ, Steinberg SM, et al. Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. Int J Radiat Oncol Biol Phys Mar;14(3): Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al. Clinical stage 1 non-hodgkin s lymphoma: long-term follow-up patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer Jun;69(6): Kelsey SM, Newland AC, Hudson GV, Jelliffe AM. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-hodgkin s lymphoma. Med Oncol. 1994;11(1): /10
9 Follicular Lymphoma 13. Seymour JF, McLaughlin P, Fuller LM, et al. High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Ann Oncol Feb;7(2): Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas; watchful waiting v aggressive combined modality treatment. Semin Hematol Apr;25(2 Suppl 2): Portlock CS, Rosenberg SA. No initial therapy for stage III and IV non-hodgkin s lymphomas of favorable histologic types. Ann Intern Med Jan;90(1): Portlock CS, Rosenberg SA, Glatstein E, Kaplan HS. Treatment of advanced non- Hodgkin s lymphomas with favorable histology: preliminary results of a prospective trial. Blood May;47(5): Rosenberg SA. Karnofsky memorial lecture. The low-grade non-hodgkin s lymphomas: challenges and opportunities. J Clin Oncol Mar;3(3): Redman JR, Cabanillas F, Velasquez WS, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol May;10(5): Solal-Celigny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d Etude des Lymphomes de l Adulte. J Clin Oncol Feb;14(2): Saven A, Emanuele S, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-hodgkin s lymphoma. Blood Sep 1;86(5): Hoppe RT, Kushlan P, Kaplan HS, et al. The treatment of advanced stage favorable histology non-hodgkin s lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood Sep;58(3): Ezdinli EZ, Anderson JR, Melvin F, et al. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol Jun;3(6): Dana BW, Dahlberg S, Nathwani BN, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol Apr;11(4): Hagenbeek A, Carde P, Meerwaldt JH, et al. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-hodgkin s lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol Jan;16(1):41-7. Toronto-Sunnybrook Regional Cancer Centre Hematology Site Group - Treatment Policies 9/10
10 25. Peterson BA, Petroni GR, Oken MM, et al. Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas: an intergroup phase III trial (CALGB 8691 and EST 7486). Proc Am Soc Clin Oncol 16, A-48, 14a, Arranz R, Garcia-Alfonso P, Sobrino P, et al. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-hodgkin s lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol Apr;16(4): Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol Jan;13(1): Bartlett NL, Rizeq M, Dorfman RF, et al. Follicular large-cell lymphoma: intermediate or low grade? J Clin Oncol Jul;12(7): Weisdorf DJ, Andersen JW, Glick JH, Oken MM. Survival after relapse of low-grade non-hodgkin s lymphoma: implications for marrow transplantation. J Clin Oncol Jun;10(6): Hochster HS, Kim K, Green MD, et al. Activity of fludarabine in previously treated non-hodgkin s low-grade lymphoma: results of an Eastern Cooperative Oncology Group Study. J Clin Oncol Jan;10(1): Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxyadenosine treatment of lowgrade lymphomas. J Clin Oncol Mar;10(3): McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol Apr;14(4): McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-cd20 monoclonal antibody therapy for relapsed indolent lymphoma; half of patients respond to a four-dose treatment program. J Clin Oncol Aug;16(8): Laport GF, Williams SF. The role of high-dose chemotherapy in patients with Hodgkin s disease and non-hodgkin s lymphoma. Semin Oncol Aug;25(4): Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol Jul;13(7): /10
Frequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationMALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationollicular Lymphoma The following investigations are indicated for most patients with follicular lymphoma:
ollicular Lymphoma Drs. Kevin Imrie & Matthew Cheung Updated August 2007* Fximab Updates: Ritu maintenance therapy Introduction Follicular lymphoma is the second most frequent type of non-hodgkin s lymphoma
More informationJ Clin Oncol 23:8447-8452. 2005 by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 33 NOVEMBER 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma Richard I. Fisher, Michael
More informationA 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
More informationCHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More information亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引
前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金
More informationLymphoma Diagnosis and Classification
Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various
More informationAgustin Avilés 1, Serafin Delgado 2, Alejandra Talavera 3, Natividad Neri 3, Judith Huerta-Guzmán 3
Eur J Haematol 2002: 68: 144 149 Printed in UK. All rights reserved Copyright # Blackwell Munksgaard 2002 EUROPEAN JOURNAL OF HAEMATOLOGY ISSN 0902-4441 Combined therapy in advanced stages (III and IV)
More informationNon-Hodgkin s lymphomas (NHLs) are a
Oncology 33 Non-Hodgkin s lymphoma in the elderly The incidence of non-hodgkin s lymphoma (NHL) is increasing, and this increase is even more rapid in the older population. Although treatment of NHL in
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationTherapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma
a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University
More informationPROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA
2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate
More informationTwo Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
Two Retroperitoneal Low-Grade B-Cell Lymphoma Successfully Treated With a Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy Yoichi Kitamura, MD Kazuhiko Hayashi, MD Kazumi Uchida,
More informationGuidelines for the Management of Follicular Lymphoma
Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World
More informationHistopathologic results
Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationNon-Hodgkin Lymphoma Richard Orlowski, MD
Non-Hodgkin Lymphoma Richard Orlowski, MD The American Cancer Society (ACS) estimates that 69,740 Americans will be diagnosed with non-hodgkin lymphoma (NHL) in 2013. Excluding non-melanoma skin cancers,
More informationAn overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationHOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1
HOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1 This document describes the minimally required staging and evaluation procedures and response criteria that will be applied in all
More informationFollicular Lymphoma. Aruna K. Reddy, MD. Hematology& Oncology Peace Health Southwest Medical Center
Follicular Lymphoma Aruna K. Reddy, MD Hematology& Oncology Peace Health Southwest Medical Center Follicular Lymphoma Malignant neoplasm resulting from clonal proliferation of malignant B-cells Second
More informationGuidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)
Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Version History Version Date Summary of Change/Process 2.0 08.05.08 Endorsed by the Governance Committee 2.1 16.02.11 Circulated at
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationSummary. 516 THE LANCET Vol 362 August 16, 2003 www.thelancet.com For personal use. Only reproduce with permission from The Lancet
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-hodgkin lymphoma: a randomised controlled trial K M Ardeshna, P Smith, A Norton, B W
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationFollicular lymphoma. What is follicular lymphoma? Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.
Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.uk is a cancer of the lymphatic system, a type of non-hodgkin lymphoma. Even though more than 12,000 people are diagnosed
More informationLymphoma: The Roleof Nurses in the Treatment Process
Lymphoma: The Roleof Nurses in the Treatment Process Sarah Liptrott MSc,BN(Hons), RN Istituto Europeo di Oncologia, Milan (IT) EBMT Swiss Study Day 2014, Zurich, Switzerland LymphomaManagement Watch &
More informationLYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
More informationAnti-HCV therapy in HCV-related NHL
Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral
More informationWaldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP
Waldenström Macroglobulinemia: The Burning Questions IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Are my kids going to get this? Familial seen in approximately 5 10% of all CLL patients and can be associated
More informationWhat is non-hodgkin lymphoma, how is it treated, and what is the unmet need?
What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationState-of-the-Art Treatment for Lymphoma December 19, 2007 Guests: David Maloney, M.D., Ph.D Hosted by Andrew Schorr INTRODUCTION
State-of-the-Art Treatment for Lymphoma December 19, 2007 Guests: David Maloney, M.D., Ph.D Hosted by Andrew Schorr Please remember the opinions expressed on Patient Power are not necessarily the views
More informationRituximab in the Management of Follicular Lymphoma
Hong Kong J Radiol. 2011;14(Suppl):S63-7 REVIEW ARTICLE Rituximab in the Management of Follicular Lymphoma YL Kwong Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong
More informationSummary & Conclusion
The prognostic value of angiogenesis markers in patients with non-hodgkin lymphoma. Summary & Conclusion The current study aims to asses the prognostic value of some angiogenesis markers in patients with
More informationUpdate on Follicular Lymphoma. Brad Kahl, M.D.
Update on Follicular Lymphoma Brad Kahl, M.D. Follicular Lymphoma: 25% of NHL Cases Other subtypes (9%) T and NK cell (12%) Burkitt (2.5%) Diffuse large B cell (DLBCL) (30%) Mantle cell (6%) Follicular
More informationDavid Loew, LCL MabThera
MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More information6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic
Follicular and Other Slow Growing Lymphomas Stephen Ansell, MD, PhD Mayo Clinic 1 Learning Objectives Start with an overview of Follicular and other slow growing lymphomas Discuss current and emerging
More informationInteresting Case Series. Periorbital Richter Syndrome
Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon,
More informationChronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.
Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates
More information6 CHEMOTHERAPY OF FOLLICULAR LYMPHOMAS
Prolonged Single-Agent Versus Combination Chemotherapy in Indolent Follicular Lymphomas: A Study of the Cancer and Leukemia Group B By Bruce A. Peterson, Gina R. Petroni, Glauco Frizzera, Maurice Barcos,
More informationLymphomas after organ transplantation
Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative
More informationBendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationMany people with non-hodgkin lymphoma have found an educational support group helpful. Support
Track 2: Treatment Options [Narrator] Many people with non-hodgkin lymphoma have found an educational support group helpful. Support groups take many forms: some meet the needs of people with all kinds
More informationGuidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre
Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection
More informationLow grade non-hodgkin Lymphoma
Low grade non-hodgkin Lymphoma www.lymphomas.org.uk The knowledge to challenge lymphatic cancers The Lymphoma Association provides: freephone helpline emotional support for those affected by lymphomas
More informationEarly stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?
Michallet et al. Journal of Hematology & Oncology 2013, 6:45 JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH Open Access Early stage follicular lymphoma: what is the clinical impact of the first-line treatment
More informationNon-Hodgkin s Lymphoma
LYMPHOMA Non-Hodgkin s Lymphoma About 71,380 people living in the United States will be diagnosed with lymphoma in 2007. This figure includes approximately 8,190 new cases of Hodgkin lymphoma (4,470 males
More informationHodgkin and Non-Hodgkin Lymphoma Pre-HCT Data
(Form 2018) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data Form. E-mail comments regarding the content
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationSOUTHWEST ONCOLOGY GROUP CLINICAL RESEARCH ASSOCIATE (CRA) MANUAL. MYELOMA CHAPTER 10 REVISED: March 2008
Introduction This disease site includes the following three malignancies: multiple myeloma, amyloidosis, and waldenstrom's macroglobulinemia. See pages 4 and 5 for descriptions of the latter two diseases.
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Study Concepts Follicular Lymphomas Mantel Cell Lymphomas Waldenstroem s Disease Key Steps in Improving Treatment for Follicular
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationPET/CT in Lymphoma. Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto
PET/CT in Lymphoma Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto Outline 1. Introduction: PET/CT, how does it work? 2.Current
More informationSalvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma
IMAJ VOL 11 January 9 Salvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma Ariela Dortort Lazar MD 1,, Ofer Shpilberg
More informationLYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis
LYMPHOMA IN DOGS Lymphoma is a relatively common cancer in dogs. It is a cancer of lymphocytes (a type of white blood cell) and lymphoid tissues. Lymphoid tissue is normally present in many places in the
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationSonneveld, P; de Ridder, M; van der Lelie, H; et al. J Clin Oncology, 13 (10) : 2530-2539 Oct 1995
Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advanced Diffuse Non-Hodgkin's Lymphoma Using CHOP Versus CNOP Chemotherapy. Sonneveld, P; de Ridder, M; van der Lelie,
More informationRituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma
Issue date: June 2011 Rituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma This guidance was developed using the the single technology appraisal process NICE technology
More informationLymphoma. Measurability of Quality Performance Indicators Version 2.0
Lymphoma Measurability of Quality Performance Indicators Version 2.0 To be read in conjunction with: Lymphoma Clinical Quality Performance Indicators (September 2013) Lymphoma Data Definitions V2.0 (September
More informationRADIATION THERAPY FOR LYMPHOMA. Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY
RADIATION THERAPY FOR Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY FACTS ABOUT The lymphatic system is a network of tiny vessels extending
More informationMichael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto
Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory
More informationRituximab in non-hodgkin Lymphoma (NHL)
Original Article ISSN: 2070-254X Rituximab in non-hodgkin Lymphoma (NHL) Manal Elhabbash MD 1, Abukris Alwindi MD 2 (1) Assistant Professor, Tripoli University, (2) Medical consultant in oncology & hematology
More informationSocial inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH)
Session 3 : Epidemiology and public health Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH) Le Guyader-Peyrou Sandra Bergonie Institut Context:
More informationCollaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY
Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular
More informationLymphoma Overview Joseph Leach, MD
Lymphoma Overview Joseph Leach, MD 71 year old male presents with complaints of mild fa5gue and a visible mass in the le: supraclavicular region PE demonstrates a firm easily palpable mass in the le: supraclavicular
More informationwww.e-mercy.com Mercy Health Fairfield Hospital Annual Report on 2010 Activities Non-Hodgkin Lymphoma Outcomes Study
www.e-mercy.com Mercy Health Fairfield Hospital Annual Report on 2010 Activities Non-Hodgkin Lymphoma Outcomes Study Cancer Program Summary The Cancer Program at Mercy Health - Fairfield Hospital has maintained
More informationThe role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D.
The role of chemotherapy in follicular lymphomas Emanuele Zucca, M.D. Oncology Institute of Southern Switzerland (IOSI) Swiss Group for Clinical Cancer Research (SAKK) WHO grading of follicular lymphoma
More informationAudience Response Question?
Presenter Disclosure Information Session 4: 3:30 PM - 4:15 PM Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman, MD The following relationships
More informationMantle Cell Lymphoma and New Treatments on the Horizon
MANTLE CELL LYMPHOMA Mantle Cell Lymphoma and New Treatments on the Horizon Presented by James Armitage, MD University of Nebraska Medical Center Pierluigi Porcu, MD The Ohio State University Comprehensive
More informationPerspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data
Perspectives on Recent Non-Hodgkin s Lymphoma (NHL) Data Summary Article James O. Armitage, MD Presented through a strategic collaboration by A series of 5 expert interviews were conducted, focusing on
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007
More informationPractice of Interferon Therapy
Interferon Therapy Practice of Interferon Therapy Multiple myeloma and other related hematological malignancies JMAJ 47(1): 32 37, 2004 Akihisa KANAMARU* and Takashi ASHIDA** *Professor, **Lecturer, Department
More informationDiffuse large B-cell lymphoma: the curable disease?
Hematology Meeting Reports 2007; 1(5):77 86 Diffuse large B-cell lymphoma: the curable disease? Michael Pfreundschuh Med Klinik I, Saarland University Medical School, Homburg/Saar, Germany Corresponding
More informationAudience Response Question? Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management. Presenter Disclosure Information
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM Miami, FL December 18, 2009 Non-Hodgkin s Lymphomas: Optimizing Therapeutic Choices for Initial Management Speaker: Arnold S. Freedman,
More informationIntroduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib
More informationDE Tsai 1, HCF Moore 1, CL Hardy 2, DL Porter 1, EY Loh 1, DJ Vaughn 1, S Luger 1, SJ Schuster 1 and EA Stadtmauer 1
Bone Marrow Transplantation, (1999) 24, 521 526 1999 Stockton Press All rights reserved 0268 3369/99 $15.00 http://www.stockton-press.co.uk/bmt Rituximab (anti-cd20 monoclonal antibody) therapy for progressive
More informationLymphoma: An Overview. Dr Louise Connell 05/03/2103
Lymphoma: An Overview Dr Louise Connell 05/03/2103 Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis/Staging Treatment/Prognosis Stem cell transplantation What is
More informationLong Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia
Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In
More informationLeukaemia and lymphoma what s the difference?
Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.uk Leukaemia and lymphoma what s the difference? This is a difficult question to answer simply but it is one that is often
More informationIn the last decade, passive immunotherapy
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Immunotherapy with Rituximab in Follicular Lymphomas Carmen SAGUNA, MD a ; Ileana Delia MUT, MD, PhD a ; Anca Roxana LUPU, MD, PhD a ; Mihaela TEVET,
More informationNon-Hodgkin s Lymphoma
Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant
More informationUNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD
UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. Petitioner, v. Biogen Idec, Inc.
More informationNATIONAL CANCER INSTITUTE. Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
NATIONAL CANCER INSTITUTE Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Basic Trial Information Phase Type Status Age Sponsor Protocol IDs Phase
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationACUTE MYELOID LEUKEMIA (AML),
1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly
More informationIntroduction of Rituximab in Front-Line and Salvage Therapies Has Improved Outcome of Advanced-Stage Follicular Lymphoma Patients
2077 Introduction of Rituximab in Front-Line and Salvage Therapies Has Improved Outcome of Advanced-Stage Follicular Lymphoma Patients Stefano Sacchi, MD 1 Samantha Pozzi, MD 1 Luigi Marcheselli, MS 1
More information